<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE325nnn/GSE325506/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Other</omics_type><species>Homo sapiens</species><gds_type>Other</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE325506</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>HSV-1 temporally orchestrates RAP80 ubiquitination to balance viral replication and evasion [Hi-C]</name><description>The mechanisms governing the complete replication cycle of herpes simplex virus type 1 (HSV-1) remain incompletely elucidated. Here, we showed that HSV-1 employs a biphasic strategy to dynamically regulate the host protein RAP80 through stage-specific ubiquitination, thereby coordinating its replication cycle. Upon entry, RAP80 undergoes phase separation to form antiviral condensates that encapsulate the viral genome and suppress viral transcription. The HSV-1-encoded E3 ubiquitin ligase ICP0 counteracts this antiviral mechanism by mediating RAP80 ubiquitination to dissolve these condensates, facilitating viral replication. In middle stage, RAP80 depletion leads to accumulation of R-loops and activation of the cGAS–STING–apoptosis axis, threatening viral persistence. In response, in middle and late stage, the viral deubiquitinase UL36USP deubiquitinates and stabilizes RAP80 to suppress R-loop accumulation and this immune-triggered apoptosis. This biphasic regulation of a single host factor represents a sophisticated viral strategy to ensure productive replication and dissemination. Notably, pharmacological disruption of RAP80 ubiquitination using engineered inhibitory peptides potently inhibits HSV-1 replication in vitro and in vivo. Furthermore, RAP80 inhibition enhances both chemosensitivity and oncolytic virotherapy in tumors. These findings reveal a ubiquitination-mediated host–pathogen equilibrium with therapeutic potential in antiviral and anticancer contexts.</description><dates><publication>2026/03/20</publication></dates><accession>GSE325506</accession><cross_references><GSM>GSM9605332</GSM><GSM>GSM9605310</GSM><GSM>GSM9605331</GSM><GSM>GSM9605330</GSM><GSM>GSM9605319</GSM><GSM>GSM9605318</GSM><GSM>GSM9605339</GSM><GSM>GSM9605317</GSM><GSM>GSM9605338</GSM><GSM>GSM9605316</GSM><GSM>GSM9605315</GSM><GSM>GSM9605337</GSM><GSM>GSM9605336</GSM><GSM>GSM9605314</GSM><GSM>GSM9605335</GSM><GSM>GSM9605313</GSM><GSM>GSM9605312</GSM><GSM>GSM9605334</GSM><GSM>GSM9605333</GSM><GSM>GSM9605311</GSM><GSM>GSM9605321</GSM><GSM>GSM9605320</GSM><GSM>GSM9605309</GSM><GSM>GSM9605308</GSM><GSM>GSM9605329</GSM><GSM>GSM9605307</GSM><GSM>GSM9605306</GSM><GSM>GSM9605328</GSM><GSM>GSM9605327</GSM><GSM>GSM9605305</GSM><GSM>GSM9605304</GSM><GSM>GSM9605326</GSM><GSM>GSM9605325</GSM><GSM>GSM9605324</GSM><GSM>GSM9605323</GSM><GSM>GSM9605322</GSM><GPL>34284</GPL><GSE>325506</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>